Gravity Analytica

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

PLX 11.07.2024

SERA-AI Powered Highlights

Drug:PLX-101 taliglucerase alfa

Drug:PLX-102 Elfabrio

Diseases:Gaucher disease

Date of Upcoming Event:2024-11-14

Name of Upcoming Event:Conference Call

Full Press Release SEC Filings Our PLX Tweets

About Gravity Analytica

Recent Filings

Company to host conference call and webcast at8:30 a.m. EST

CARMIEL,Israel,Nov. 7, 2024/PRNewswire/ --Protalix BioTherapeutics, Inc.(NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^®plant cell–based protein expression system, today announced that it will release its financial results for the quarter endedSeptember 30, 2024and provide a business and clinical update onNovember 14, 2024.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:Date:Thursday, November 14, 2024Time:8:30 a.m. Eastern Standard Time (EST)Toll Free:1-877-423-9813International:1-201-689-8573Israeli Toll Free:1-809-406-247Conference ID:13749493Call meTM:https://tinyurl.com/2n9fhumh

The Call meTM feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details:Company Link:https://ir.protalix.com/news-events/eventsWebcast Link:https://tinyurl.com/3be68pkwConference ID: 13749493

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

AboutProtalix BioTherapeutics, Inc.Protalixis a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gainU.S. Food and Drug Administration(FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.Protalixhas licensed toPfizer Inc.the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease,Protalix'sfirst product manufactured through ProCellEx, excluding inBrazil, whereProtalixretains full rights.Protalix'ssecond product, Elfabrio^®, was approved by both the FDA and theEuropean Medicines AgencyinMay 2023.

Protalixhas partnered withChiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio.Protalix'sdevelopment pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Logo -https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

Investor ContactMike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306mmoyer@lifesciadvisors.com

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-third-quarter-2024-financial-and-business-results-on-november-14-2024-302298569.html

SOURCEProtalix BioTherapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com